Symbiotic-GI-03: A randomized, double-blind, phase 3 study of first-line PF-08634404, a PD-1/VEGF bispecific antibody, in combination with mFOLFOX6 in patients with metastatic colorectal cancer (mCRC).
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Vanderbilt-Ingram Cancer Center, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Inserm, Université Paris Cité, Sorbonne Université, Centre de Recherche des Cordeliers, Assistance Publique – Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Sun Yat-sen University, Aichi Cancer Center, Mayo Clinic in Arizona, Mayo Clinic Hospital, Mayo Clinic Comprehensive Cancer Center (Arizona), Peter MacCallum Cancer Centre, The Netherlands Cancer Institute, Shanghai Medical College of Fudan University, Fudan University, Duke University, Duke Medical Center, Asan Medical Center, University of Ulsan, Texas Oncology, University of Opole, Pfizer (United States), Dana-Farber Cancer Institute
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162697203
Cites:
Cited by:
Related to: